Zobrazeno 1 - 10
of 103
pro vyhledávání: ''
Autor:
Jordi Rodon, Joann Lim, Elizabeth A. Sumner, Hira Zain, Di Nguyen, Jack P. Higgins, Vivek Subbiah, Funda Meric-Bernstam, Eric T Williams, Coline Agnes Couillault, Siqing Fu, Timothy A. Yap, Kimal Rajapakshe, Aparna Hegde, Sarina Anne Piha-Paul, Shubham Pant, Michael A. Curran, Priya Bhosale, Priyamvada Jayaprakash, David S. Hong, Thomas F. Wilson, Daniel D. Karp, Ecaterina Ileana Dumbrava, Ly M. Nguyen, Cristian Coarfa
Publikováno v:
Clin Cancer Res
Purpose: As hypoxia can mediate resistance to immunotherapy, we investigated the safety, tolerability, and efficacy of combining evofosfamide, a prodrug that alleviates hypoxia, with ipilimumab, an immune checkpoint inhibitor, in immunologically “c
Autor:
Phillip L. Palmbos, Przemyslaw Twardowski, Vivek K. Arora, Alicia K. Morgans, Dan R. Robinson, Karen E. Knudsen, Matthew S. Davenport, Maha Hussain, Neeraj Agarwal, Javed Siddiqui, Emmanuel S. Antonarakis, Jon A. Jacobson, Stephanie Daignault-Newton, Scott A. Tomlins, Wm. Kevin Kelly, Arul M. Chinnaiyan
Publikováno v:
Clin Cancer Res
Purpose: Palbociclib, a cyclin-dependent kinase (CDK) 4/6 inhibitor, blocks proliferation in a RB and cyclin D–dependent manner in preclinical prostate cancer models. We hypothesized that cotargeting androgen receptor and cell cycle with palbocicli
Autor:
Guanghui Gao, Zhe-Hai Wang, Jifeng Feng, Meijuan Huang, Xinmin Yu, Zhihua Liu, Caicun Zhou, Lihong Wu, Yina Wang, Ying Cheng, Jun Zhao, Yuan Chen, Zhiyong Ma, Weixia Li, Xiaoyan Lin, Shengxiang Ren, Kangsheng Gu, R. Guo, Jun Zhang, Quan Ren Wang, Xinfeng Yang, Gongyan Chen, Yu Yao, Jianxing He, Jianhua Chen, Jianhua Shi
Publikováno v:
Clinical Cancer Research. 27:1296-1304
Purpose: Our preclinical work suggests that appropriate angiogenesis inhibition could potentiate PD-1/PD-L1 blockade via alleviating hypoxia, increasing infiltration of CD8+ T cells and reducing recruitment of tumor-associated macrophages. We hereby
Autor:
Abdulkhaliq Alsaadi, Christina Fotopoulou, Eric O. Aboagye, Jennifer Ploski, Mara Artibani, Paula Cunnea, Sarah P. Blagden, Ashwag Albukhari, Oloruntoba I. Osagie, Sunanda Dhar, Joanna Hester, Leticia Campo, Laura Santana Gonzalez, Katherine Nixon, Zhiyuan Hu, Christopher Yau, Haonan Lu, Nina Wietek, Ahmed Ashour Ahmed, Stephen Damato, Zhe Zhong
Publikováno v:
Clinical cancer research, 27(5), 1570-1579. American Association for Cancer Research Inc.
Purpose: Using RNA sequencing, we recently developed the 52-gene–based Oxford classifier of carcinoma of the ovary (Oxford Classic, OxC) for molecular stratification of serous ovarian cancers (SOCs) based on the molecular profiles of their cell of
Autor:
Massimo Cristofanilli, Kalliopi P. Siziopikou, Qiang Zhang, Lisa Flaum, Andrew M. Davis, Lorenzo Gerratana, Ami N. Shah, Amir Behdad, Leonidas C. Platanias, Neelima Katam, Saya Jacob, William J. Gradishar, Aditya Bardia, Firas Wehbe, Marko Velimirovic
Publikováno v:
Clinical Cancer Research. 27:1361-1370
Purpose: Circulating tumor DNA (ctDNA) is a promising tool for noninvasive longitudinal monitoring of genomic alterations. We analyzed serial ctDNA to characterize genomic evolution in progressive metastatic breast cancer. Experimental Design: This w
Autor:
Hans-Peter Sinn, Christian Schem, Frederick Klauschen, Karsten Weber, Andreas Schneeweiss, Elmar Stickeler, Marion von Mackelenbergh, Dirk Michael Zahm, Sibylle Loibl, Bruno Valentin Sinn, Denise Treue, Claus Hanusch, Frederik Marmé, Clemens Becker, Michael Untch, Jenny Furlanetto, Carsten Denkert, Thomas Karn, Nicole Burchardi, Peter A. Fasching, Wolfgang D. Schmitt, Volkmar Müller
Publikováno v:
Clinical Cancer Research. 27:2584-2591
Purpose: We evaluated mRNA signatures to predict response to neoadjuvant PD-L1 inhibition in combination with chemotherapy in early triple-negative breast cancer. Experimental Design: Targeted mRNA sequencing of 2,559 transcripts was performed in for
Autor:
Chiara Cremolini, Axel Grothey, Jim Abraham, Donald A. Berry, David D. Halbert, Mohamed E. Salem, Michael J. Hall, Matthew J. Oberley, Anthony Helmstetter, Carlotta Antoniotti, W. Michael Korn, Anthony F. Shields, David Spetzler, John L. Marshall, Alfredo Falcone, Phillip Stafford, Daniel Magee, Joanne Xiu, Heinz-Josef Lenz, Alan P. Venook
Publikováno v:
Clinical Cancer Research. 27:1174-1183
Purpose: FOLFOX, FOLFIRI, or FOLFOXIRI chemotherapy with bevacizumab is considered standard first-line treatment option for patients with metastatic colorectal cancer (mCRC). We developed and validated a molecular signature predictive of efficacy of
Autor:
Nathalie Andrieu-Abadie, Muriel Mounier, Pascale Olivier, Thierry Levade, Mathieu Virazels, Jean Milhès, Carine Dufau, Maha Ayyoub, Bruno Ségui, Cécile Pagès, Amélie Lusque, Jean-Pierre Delord, Stéphanie Brayer, Céline Colacios, Thomas Filleron, Anne Montfort, Nicolas Meyer
Publikováno v:
Clinical Cancer Research. 27:1037-1047
Purpose: TNF blockers can be used to manage gastrointestinal inflammatory side effects following nivolumab and/or ipilimumab treatment in patients with advanced melanoma. Our preclinical data showed that anti-TNF could promote the efficacy of immune
Autor:
Vinay Raja, Micki Prager, Marc Hoffmann, Qamar J. Khan, Sheshadri Madhusudhana, Larry Beck, Lauren Nye, Rajvi H. Shah, Jaimie Heldstab, Dinesh Pal Mudaranthakam, Stephanie LaFaver, Roy A. Jensen, Roberto Rodríguez, Kelsey E. Larson, Gregory James Crane, Amanda L. Amin, Richard McKittrick, Venkatadri Beeki, Joshua M Staley, Lindsey Prochaska, Roberto Salgado, Maureen Sheehan, Rachel Yoder, Andrew K. Godwin, Manana Elia, Bruce F. Kimler, Larry Corum, Anuj Shrestha, Priyanka Sharma, Kathan Mehta, Christa R. Balanoff, Deepti Satelli, Jamie L. Wagner, Anne O'Dea, Milind A. Phadnis, Robert Pluenneke, Yen Y. Wang, Karissa Finke
Publikováno v:
Clin Cancer Res
Purpose: Addition of carboplatin (Cb) to anthracycline chemotherapy improves pathologic complete response (pCR), and carboplatin plus taxane regimens also yield encouraging pCR rates in triple-negative breast cancer (TNBC). Aim of the NeoSTOP multisi
Autor:
Takako Eguchi Nakajima, Keiko Minashi, Shuichi Hironaka, Tomohiro Nishina, Takeharu Yamanaka, Takeshi Kajiwara, Naoki Izawa, Kei Muro, Yutaka Kawakami, Yuichiro Hayashi, Shigenori Kadowaki
Publikováno v:
Clinical Cancer Research. 27:1029-1036
Purpose: We conducted a phase I/II study to investigate the safety and efficacy of nivolumab with paclitaxel plus ramucirumab. Patients and Methods: Patients with advanced gastric cancer (AGC) refractory to first-line chemotherapy were included. Pati